Table 1.
Participant characteristics.
| Characteristic | Total Cohort (n = 38) |
|---|---|
| Age, years 1 | 57 (8) |
| Male sex, n (%) | 22 (58) |
| Diagnosis, n (%) | |
| Multiple myeloma | 23 (61) |
| Lymphoma | 12 (32) |
| Acute myeloid leukemia | 3 (8) |
| Transplant, n (%) | |
| Autologous | 32 (86) |
| Allogeneic | 5 (14) |
| Conditioning regimen, n (%) | |
| Melphalan | 23 (61) |
| Carmustine, Cytarabine, Etoposide, Melphalan | 8 (22) |
| Carmustine, Thiotepa | 1 (3) |
| Alemtuzumab, Fludarabine, Melphalan | 1 (3) |
| Fludarabine, Cytarabine, Amsacrine, Busulfan, Anti-thymocyte globulin | 1 (3) |
1 Data is presented as mean (SD) unless specified otherwise.